Education
About Us
Working with TipRanks
Follow Us
FTXH - AI Analysis
Top Page
First Trust Nasdaq Pharmaceuticals ETF (FTXH)
Rating:71Outperform
Price Target:
$32.00
Positive Factors
Strong Top Holdings
Several key holdings, such as Johnson & Johnson, AbbVie, and Gilead Sciences, have delivered strong year-to-date performance, supporting the ETF's overall returns.
Sector Focus on Health Care
The ETF's heavy exposure to the health care sector provides stability, as this industry tends to perform well during economic uncertainty.
Steady Recent Performance
The ETF has shown consistent gains over the past three months and year-to-date, indicating solid momentum.
Negative Factors
High Sector Concentration
With over 99% of its portfolio in health care, the ETF is highly exposed to risks specific to this sector.
Underperforming Holdings
Several top holdings, including Merck, Pfizer, and Bristol-Myers Squibb, have lagged in performance, which could weigh on future returns.
Limited Geographic Diversification
The ETF is almost entirely focused on U.S. companies, offering little exposure to international markets.
FTXH vs. SPDR S&P 500 ETF (SPY)
AUM17.68M
RegionNorth America
Expense Ratio0.60%
Beta0.59
IssuerFirst Trust
Inception DateSep 20, 2016
Dividend Yield1.58%
Asset ClassEquity
Index TrackedNasdaq US Smart Pharmaceuticals Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume2,382
30 Day Avg. Volume2,933
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
33.79Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering51
FTXH Summary
The First Trust Nasdaq Pharmaceuticals ETF (FTXH) is an investment fund that focuses on pharmaceutical companies within the health care sector. It follows the Nasdaq US Smart Pharmaceuticals Index and includes well-known companies like AbbVie and Johnson & Johnson. This ETF is a good choice for investors who want to benefit from the growth potential of the pharmaceutical industry, driven by advancements in drug development and biotechnology. However, new investors should be aware that the ETF’s performance is closely tied to the health care sector, which can be affected by regulatory changes and market fluctuations.
How much will it cost me?The First Trust Nasdaq Pharmaceuticals ETF (FTXH) has an expense ratio of 0.6%, meaning you’ll pay $6 per year for every $1,000 invested. This is higher than average because it is actively managed and focuses on a specialized sector, which typically involves more research and management costs.
What would affect this ETF?The FTXH ETF could benefit from advancements in pharmaceutical research, including breakthroughs in drug development and personalized medicine, as well as increased demand for innovative health care solutions in the U.S. However, it may face challenges from regulatory changes, patent expirations, or economic downturns that could impact the profitability of its top holdings like AbbVie, Johnson & Johnson, and Merck.
FTXH Top 10 Holdings
The First Trust Nasdaq Pharmaceuticals ETF (FTXH) is heavily concentrated in U.S. pharmaceutical giants, with AbbVie, Johnson & Johnson, and Merck leading the charge. AbbVie and Johnson & Johnson are rising steadily, buoyed by strong earnings and strategic R&D investments, while Merck faces mixed performance due to competitive pressures. On the weaker side, Pfizer and Bristol-Myers Squibb are lagging, weighed down by technical weakness and revenue challenges. With nearly all holdings rooted in health care, this fund offers a focused play on the pharmaceutical sector, though its reliance on a few big names could amplify volatility.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| AbbVie | 7.45% | $1.32M | $401.96B | 20.10% | 64 Neutral | |
| Johnson & Johnson | 7.27% | $1.28M | $450.37B | 16.76% | 78 Outperform | |
| Merck & Company | 7.13% | $1.26M | $217.38B | -16.10% | 76 Outperform | |
| Pfizer | 6.82% | $1.21M | $139.30B | -13.91% | 78 Outperform | |
| Bristol-Myers Squibb | 6.25% | $1.11M | $87.16B | -18.44% | 66 Neutral | |
| Regeneron | 3.88% | $685.90K | $69.37B | -29.42% | 79 Outperform | |
| Eli Lilly & Co | 3.86% | $681.50K | $776.19B | -9.24% | 70 Outperform | |
| Biogen | 3.81% | $674.37K | $21.86B | -18.72% | 77 Outperform | |
| Cardinal Health | 3.77% | $666.30K | $38.68B | 47.91% | 65 Neutral | |
| Vertex Pharmaceuticals | 3.72% | $657.66K | $108.30B | -10.20% | 75 Outperform |
FTXH Technical Analysis
Positive
―
Price Trends
28.46
Positive
27.32
Positive
26.79
Positive
Market Momentum
0.31
Positive
59.75
Neutral
81.57
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For FTXH, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 29.31, equal to the 50-day MA of 28.46, and equal to the 200-day MA of 26.79, indicating a bullish trend. The MACD of 0.31 indicates Positive momentum. The RSI at 59.75 is Neutral, neither overbought nor oversold. The STOCH value of 81.57 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FTXH.
FTXH Peer Comparison
Comparison Results
Performance Comparison
FTXH
First Trust Nasdaq Pharmaceuticals ETF
29.40
1.51
5.41%
XHS
SPDR S&P Health Care Services ETF
―
―
―
SBIO
ALPS Medical Breakthroughs ETF
―
―
―
LFSC
F/M Emerald Life Sciences Innovation ETF
―
―
―
IBBQ
Invesco Nasdaq Biotechnology ETF
―
―
―
BBP
Virtus LifeSci Biotech Products ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents